TrialCancer research2025

Oxidative Phosphorylation Is a Metabolic Vulnerability of Endocrine Therapy-Tolerant Persister Cells in ER+ Breast Cancer.

Steven Tau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.